Search by product name, CAS, target or catalog number. Press Down Arrow to reach product suggestions, Tab to move between links, and Escape to close suggestions.
Infectious disease antibodies bind viral envelope proteins or bacterial toxins for neutralization and infection studies. Sotrovimab, casirivimab and bamlanivimab bind the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Palivizumab and nirsevimab neutralize respiratory syncytial virus (RSV) by binding its fusion protein. Bezlotoxumab binds Clostridioides difficile toxin B, while raxibacumab and obiltoxaximab neutralize the protective antigen of anthrax toxin. Further antibodies target human immunodeficiency virus (HIV), influenza, hepatitis B virus and Ebola virus glycoproteins, as well as cytomegalovirus and BK virus.
Synonyms: 3BNC-117
Lafuvitug (3BNC-117) is a fully human monoclonal antibody of the IgG1 subclass that specifically targets the HIV-1 envelope glycoprotein gp120. This interaction is crucial for blocking the virus's ability to attach to and enter host cells, thus inhibiting viral replication. For experimental control purposes, the recommended isotype control is Human IgG1 kappa.
Synonyms: AZD-1061; COV2-2130
Cilgavimab (AZD-1061; COV2-2130) is a human monoclonal antibody designed to neutralize SARS-CoV-2. When combined with Tixagevimab, it forms the monoclonal antibody cocktail AZD7442. Demonstrating protective efficacy in mouse models of SARS-CoV-2 infection, Cilgavimab targets specific viral epitopes, preventing the virus from entering and infecting healthy cells. This antibody is crucial for research focused on the mechanisms of viral neutralization and the development of therapeutic strategies against COVID-19.
Synonyms: 10-1074
Zinlirvimab is a human IgG1-λ2 monoclonal antibody designed for the neutralization of HIV-1. It specifically targets the gp120 envelope glycoprotein, focusing on the IIIB gp120 V3 loop. This antibody is utilized in research to study the mechanisms of HIV entry into cells and to develop strategies for blocking this process. Zinlirvimab's high specificity and binding affinity make it an essential tool for advanced HIV research and therapeutic development.
Synonyms: BI 767551; DZIF-10c
Lomtegovimab (BI 767551) is a human monoclonal antibody that targets the spike glycoprotein of SARS-CoV-2. This antibody binds to the spike protein, effectively neutralizing the virus and demonstrating significant antiviral efficacy. Lomtegovimab is primarily utilized in research focused on the treatment and understanding of COVID-19. Its specific interaction with the SARS-CoV-2 virus makes it a valuable tool for studies aimed at virus neutralization and therapeutic intervention.
Synonyms: NM57; rhRIG
Ormutivimab (rhRIG) is a recombinant human monoclonal antibody specifically designed to target the rabies virus. This antibody demonstrates broad neutralizing activity against multiple strains of the rabies virus, making it a critical tool in post-exposure prophylaxis (PEP) models. Ormutivimab's high efficacy in neutralizing rabies virus highlights its potential as a therapeutic option in managing exposures to this lethal virus.
